287 studies found for:    "Breast Neoplasms, Male"
Show Display Options
Download search resultsDownload the search results for:
"Breast Neoplasms, Male" (287 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention:
2 Unknown  A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed
Has Results
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms, Male;   Carcinoma, Ductal
Intervention: Drug: pemetrexed
4 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
5 Completed Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: trastuzumab
6 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: questionnaire administration
7 Active, not recruiting ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: ONTAK;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
8 Active, not recruiting
Has Results
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Radiation: F-18 16 alpha-fluoroestradiol;   Procedure: positron emission tomography;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Genetic: gene expression analysis
9 Recruiting Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Conditions: Central Nervous System Metastases;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Drug: everolimus;   Drug: capecitabine;   Other: laboratory biomarker analysis
10 Not yet recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2 multiplasmid vaccine;   Other: laboratory biomarker analysis
11 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
12 Active, not recruiting Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery
Conditions: Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: paclitaxel;   Biological: bevacizumab;   Other: laboratory biomarker analysis
13 Active, not recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
14 Active, not recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Completed
Has Results
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
16 Withdrawn Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
17 Terminated
Has Results
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Extensive Stage Small Cell Lung Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Tumors Metastatic to Brain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Radiation: Whole-brain radiation therapy (WBRT);   Radiation: Stereotactic radiosurgery (SRS);   Procedure: Cognitive assessment;   Other: Laboratory biomarker analysis
18 Terminated Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: anastrozole;   Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
19 Active, not recruiting
Has Results
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysis
20 Terminated
Has Results
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years